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Introduction. Normocalcemic primary hyperparathyroidism (NPHPT) is considered a variant of the more frequent form of the
disease characterized by normal serum calcium levels with high PTH. The higher prevalence of renal stones in patients with
HPTP and the well established association with bone disorders show the importance of studies on how to manage asymptomatic
patients. Objective. To compare the clinical and laboratory data between the normocalcemic and mild hypercalcemic forms of
PHPT. Methods. We retrospectively evaluated 70 patients with PHPT, 33 normocalcemic and 37 mild hypercalcemic. Results.T h e
frequency of nephrolithiasis was 18.2% in normocalcemic patients and 18.9% in the hypercalcemic ones (P = 0.937). Fifteen
percent of normocalcemic patients had a previous history of fractures compared to 10.8% of hypercalcemic patients, although
there was no statistically signiﬁcant diﬀerence (P = 0.726). Conclusion. Our data conﬁrms a high prevalence of urolithiasis in
normocalcemic primary hyperparathyroidism, but with the preservation of cortical bone. This ﬁnding supports the hypothesis
that this disease is not an idle condition and needs treatment.
1.Introduction
Primary hyperparathyroidism (PHPT) is a disease charac-
terized by elevated or inappropriately normal parathyroid
hormone (PTH) levels due to excessive secretion by one or
more parathyroid glands. The classical form of the disease is
characterized by hypercalcemia, kidney stones, and severe
bonedisease[1].Theroutinemeasurementofserumcalcium
asa screening tool has led to a sharp increase in the incidence
of a new presentation of the disease, namely, asymptomatic
PHPT, whose demonstration of bone involvement depends
exclusively on the bone densitometry data [2–4].
The association with kidney disease, nephrocalcinosis,
and nephrolithiasis is well established in the HPTP and has
beenreportedinseveralstudies.Suhetal.foundaprevalence
of 7% in 271 individuals with the disorder and 1.6% in
500 healthy patients evaluated by sonography. The risk of
hospitalization due to urolithiasis is increased for patients
with HPTP even ten years after parathyroidectomy [5, 6].
Currently a new phenotype has arisen, in which normo-
calcemia is observed, despite persistently high levels of PTH.
In this situation, a thorough search for causes of secondary
hyperparathyroidism, particularly vitamin D deﬁciency, is
imperative [7–9]. The demonstration of normocalcemic
PHPT is even more diﬃcult as there are no guidelines for
routine PTH measurement, as HPTP is most frequently
identiﬁed during the investigation of reduced bone density
[9, 10].
2. Patients andMethods
We retrospectively reviewed the medical records of 70 pa-
tients with PHPT from our institution, who were divid-
ed into two groups: 33 patients with normal serum cal-
cium levels and 37 with hypercalcemia(serum calcium ≥
10.2mg/dL).
The following clinical data were obtained: gender, age,
weight, height, and BMI.
The diagnostic criteria for NPHPT were as follows: apart
from normal serum calcium and high PTH levels, serum
25OHD levels above 30ng/mL, absence of bisphosphonates,2 Journal of Osteoporosis
Table 1: Baseline characteristics of study patients.
Variable Normocalcemic Hypercalcemic Total P value
Gender
Male % 21.2 24.3 22.9 P = 0.757
Female % 78.8 75.7 77.1
Age(years) 63.67 ± 13.83 61.68 ± 13.86 62.61 ± 13.78 P = 0.550
BMI(Kg/m2) 25.78 ± 3.85 26.66 ± 4.25 26.25 ± 4.06 P = 0.376
Serum calcium (mg/dL) 9.58 ± 0.44 11.33 ± 0.90 10.51 ± 1.13 P<0.001
Serum creatinine(mg/dL) 0.89 ± 0.20 0.85 ± 0.32 0.86 ± 0.29 P = 0.676
Serum 25OHD(ng/mL) 42.45 ± 12.94 30.91 ± 10.63 36.68 ± 13.11 P<0.001
Serum PTH(pg/mL) 127.52 ± 114.41 226.18 ± 398.61 179.67 ± 302.38 P = 0.175
Serum CTX(pg/mL) 342.94 ± 207.16 492.13 ± 425.37 416.39 ± 338.75 P = 0.080
CrCL(mL/min/1,73) 80.08 ± 21.08 87.82 ± 34.17 84.17 ± 28.82 P = 0.253
Data expressed as mean ± SD.
thiazidediuretics,anticonvulsantsorlithiumuse,glomerular
ﬁltration rate greater than 60mL/min, using the formula
Modiﬁcation of Diet in Renal Disease(MDRD), and the ab-
sence of other metabolic bone diseases or gastrointestinal
diseases associated with malabsorption or liver disease. All
patients had a urinary Ca/Cr ratio of less than 240mg/g Cr,
demonstrating the absence of hypercalciuria.
Serum calcium was determined using the Johnson and
Johnson VITROS 950 system(Rochester, NY, USA) with ref-
erence value 8.4 to 10.2mg/dL, serum 25-hydroxyvitamin D
using the DiaSorin LIAISON competitive chemiluminescent
immunoassay(Stillwater, MN, USA) 10% coeﬃcient of
variation, with the following reference values: normal: 30 to
60ng/mL), serum PTH using the chemiluminescence meth-
od, Immulite 2000(SIEMENS, Llanberis, Gwynedd, UK),
with intra- and interassay coeﬃcients of variation of 4.2 to
5.7% and 6.3 to 6.8%, respectively, and serum C-telopeptide
when using the electrochemiluminescence assay, Elecsys sys-
tems, Roche Diagnostics, Mannheim, Germany, reference
value 50–450pg/mL. Bone mineral density(BMD) and T-
score were evaluated at the lumbar spine(L1–L4), femoral
neck, and distal radius(Lunar Corporation Madison, Wis-
consin, USA). The correction of serum calcium levels in
relation to albumin was performed using the following
formula: corrected calcium = calcium found + (4-serum
albumin) × 0.8.
Patients who had clinical manifestations of nephrolithi-
asis were evaluated by ultrasound, and the results of the
examinations were obtained from the medical records. Bone
fractures were investigated by radiography.
The study was approved by the Ethics in Research
Committee of Agamenon Magalh˜ aes Hospital.
3.StatisticalAnalysis
Pearson’s chi-square test or Fisher’s exact test and the Stu-
dent’s t-test with equal or unequal variances were used for
comparisons. Veriﬁcation of the hypothesis of equal vari-
ances was performed using Levene’s F test, and the level of
signiﬁcance used in interpreting the statistical test was 5%.
4. Results
Baseline characteristics are shown in Table 1.T h ep r e v a l e n c e
of nephrolithiasis in the normocalcemic group was 18.2%
and 18.9% in the hypercalcemic group (P = 0.937). Fifteen
percent of normocalcemic patients had a previous history
of fractures compared to 10.8% of hypercalcemic patients,
although there was no statistically signiﬁcant diﬀerence (P =
0.726) Table 2.
In both groups, the bone mineral density in the lumbar
spine was 0.95 ± 0.24g/cm2 (T score: −1.3), femoral neck
0.76 ± 0.15g/cm2 (T score: −1.75), and distal radius 0.54
± 0.15g/cm2 (T score: −1.96). LS BMD was normocalcemic
0.95 ± 0.22g/cm2 versus hypercalcemic 0.95 ± 0.26g/cm2,
P = 0.885 and FN BMD: normocalcemic 0.73 ± 0.15g/cm2
versus hypercalcemic 0.79 ± 0.19g/cm2, P = 0.123. Patients
with normocalcemia had BMD values in the distal radius
signiﬁcantly higher than the hypercalcemic patients (P =
0.046), as shown in Table 3.
5. Discussion
In the present study we found a high prevalence of kidney
stones in NPHPT, suggesting that the normocalcemia con-
dition does not mean that the patient is without clinical
manifestations. In relation to a history of fractures, we found
a similar occurrence in the two groups with 15.2% in the
normocalcemic and 10.8% in the hypercalcemic. We also
observed that the bone mineral density in the distal radius
was more preserved in the normocalcemic group than in
the hypercalcemic group, although there were no signiﬁcant
diﬀerences in the lumbar spine and femoral neck.
Few studies have addressed the issue of NPHPT. Lund-
gren et al., in a sample of 109 patients, found that 17 (16%)
had normal levels of calcium with elevated PTH characteriz-
ing NPHPT [11]. In our institution, Marques et al. found a
prevalence of NPHPT of 8.9% in a population of 156 post-
menopausal women with osteoporosis [8]. These data sug-
gest that it is not a rare condition and therefore needs to beJournal of Osteoporosis 3
Table 2: History of fracture and kidney stones in normocalcemic and hypercalcemic PHPT.
Variable
Normocalcemic Hypercalcemic Group total
P value
N%N%N%
Total 33 100,0 37 100,0 70 100,0
(i) Fracture
Yes 5
1M/4F 15.2 4
0M/4F 10.8 9 12.9 P(1) = 0.726
(ii) Kidney Stones
Yes 6
0M/6F 18.2 7
3M/4F 18.9 13 18.6 P(2) = 0.937
(1)Using Fisher’s exact test. (2)Using Pearson’s chi-square test.
M :m a l e ;F :f e m a l e .
Table 3: Bone mineral density in normocalcemic and hypercalcemic PHPT.
BMD# Normocalcemic Hypercalcemic Group total P value
(i) Distal radius 0.54 ± 0.15 0.45 ± 0.18 0.50 ± 0.17 P(1) = 0.046
(ii) Lumbar spine 0.95 ± 0.22 0.95 ± 0.26 0.95 ± 0.24 P(1) = 0.885
(iii) Femoral neck 0.73 ± 0.15 0.79 ± 0.19 0.76 ± 0.17 P(1) = 0.123
#BMD in g/m2. Data expressed as mean ± SD.
investigated in all patients with reduced bone mineral den-
sity. In contrast, in a population-based survey conducted in
Sweden, the prevalence of NPHPT, in postmenopausal
women was 0.6% [11].
The incidence of kidney stones and fractures has also
been documented in small studies. Lowe et al. [9], in a series
of 37 normocalcemic patients, found a frequency of neph-
rolithiasis of 14%, which is comparable with our ﬁndings,
and a history of fracture of 11% [9]. Marques et al. showed
an occurrence of kidney stones of 28.6% in osteoporotic
women with NPHPT in contrast to 0.7% in noncarriers. For
clinical fractures they found a 21.4% prevalence in NPHPT
compared with 16.2% in those not aﬀected [8]. Our study
showed a preservation of cortical bone in patients with the
normocalcemic form of the disease, and this is in agreement
with the ﬁndings of Lowe et al., who showed a deterioration,
particularly in LS BMD [9].
Patients with NPHPT may present PTH resistance in
target tissues. One study showed that after an oral calcium
load,normocalcemicsubjectshadaninadequatesuppression
of PTH compared with hypercalcemic subjects. The high
frequency of kidney stones and fractures in normocalcemic
primaryhyperparathyroidismcouldbeexplainedbythepos-
sible lower renal and bone sensitivity to the biological eﬀects
of PTH, although this hypothesis needs further investigation
[12]. Gomes et al. stated that another possibility could be
the presence of non-1–84 PTH circulating molecules, such as
a 7–84 PTH fragment, blocking the calcemic eﬀect of 1–84
PTH and preventing hypercalcemia [13].
Our data suggests that NPHPT may not be an idle
conditionasitmayprogresstocomplicationregardlessofthe
development of hypercalcemia. Controversies regarding the
suggestion that NPHPT should be treated, since the disease
can lead to a deterioration in bone mineral density, fractures,
and kidney stones. Thus, the routine determination of PTH
could detect these individuals early on in an attempt to pre-
vent an unfavorable clinical course.
There is no consensus about when to treat patients with
HPTPN, but if there is progression to clinical complications
such as urolithiasis, bone mass loss, or fractures, surgery is
indicated [4].
Finally, a new phenotype of NPHPT was recently de-
scribed in a population-based survey MrOS (Osteoporosis
Fractures in Men). Using less rigid criteria for the diagnosis
of NPHPT (GFR >40mL/min and serum 25OHD <20
mg/mL), the authors found a 0.7% prevalence of the disease
that was associated with a signiﬁcantly higher LS BMD in
comparison with the elderly men without NPHPT [14].
6. Conclusion
Our ﬁndings revealed a high prevalence of urolithiasis in
normocalcemic primary hyperparathyroidism, but with pre-
servation of the cortical bone, corroborating the belief that
the disease is not an indolent condition and needs to be not
only investigated but also treated when complications are
diagnosed.
References
[1] S. J. Silverberg and J. P. Bilezikian, “Primary hyperparathy-
roidism,” Endocrinology, pp. 1075–1093, 2001.
[2] S. J. Silverberg, E. Shane, L. De La Cruz et al., “Skeletal disease
in primaryhyperparathyroidism,” JournalofBone andMineral
Research, vol. 4, no. 3, pp. 283–291, 1989.
[3] S. J. Silverberg, F. G. Locker, and J. P. Bilezikian, “Verte-
bral osteopenia: a new indication for surgery in primary
hyperparathyroidism,” Journal of Clinical Endocrinology and
Metabolism, vol. 81, no. 11, pp. 4007–4012, 1996.4 Journal of Osteoporosis
[ 4 ]S .J .S i l v e r b e r g ,E .M .L e w i e c k i ,L .M o s e k i l d e ,M .P e a c o c k ,
and M. R. Rubin, “Presentation of asymptomatic primary
hyperparathyroidism. Proceedings of the 3rd International
Workshop,” Journal of Clinical Endocrinology and Metabolism,
vol. 94, no. 2, pp. 351–365, 2009.
[5] L. Rejnmark, P. Vestergaard, and L. Mosekilde, “Nephrolithi-
asis and renal calciﬁcations in primary hyperparathyroidism,”
Journal of Clinical Endocrinology and Metabolism, vol. 96, no.
8, pp. 2377–2385, 2011.
[6] J. M. Suh, J. J. Cronan, and J. M. Monchik, “Primary
hyperparathyroidism: is there an increased prevalence of renal
stone disease?” American Journal of Roentgenology, vol. 191,
no. 3, pp. 908–911, 2008.
[7] J. P. Bilezikian and S. J. Silverberg, “Normocalcemic primary
hyperparathyroidism,” Arquivos Brasileiros de Endocrinologia e
Metabologia, vol. 54, no. 2, pp. 106–109, 2010.
[8] T. F. Marques, R. Vasconcelos, E. Diniz, D. Rˆ ego, L. Griz, and
F. Bandeira, “Normocalcemic primary hyperparathyroidism
in clinical practice: an indolent condition or a silent threat?”
Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 55,
no. 5, pp. 314–317, 2011.
[9] H. Lowe, D. J. McMahon, M. R. Rubin, J. P. Bilezikian, and S.
J. Silverberg, “Normocalcemic primary hyperparathyroidism:
Further characterization of a new clinical phenotype,” Journal
of Clinical Endocrinology and Metabolism,v o l .9 2 ,n o .8 ,p p .
3001–3005, 2007.
[10] S. J. Silverberg and J. P. Bilezikian, ““Incipient” primary
hyperparathyroidism: a “Forme Fruste” of an old disease,”
Journal of Clinical Endocrinology and Metabolism, vol. 88, no.
11, pp. 5348–5352, 2003.
[11] E. Lundgren, J. Rastad, E. Thurfjell, G. ˚ Akerstr¨ om, and S.
Ljunghall, “Population-based screening for primary hyper-
parathyroidismwithserumcalciumandparathyroidhormone
values in menopausal women,” Surgery, vol. 121, no. 3, pp.
287–294, 1997.
[12] G. Maruani, A. Hertig, M. Paillard, and P. Houillier, “Nor-
mocalcemic primary hyperparathyroidism: evidence for a
generalized target-tissue resistance to parathyroid hormone,”
Journal of Clinical Endocrinology and Metabolism, vol. 88, no.
10, pp. 4641–4648, 2003.
[13] S. A. Gomes, A. Lage, M. Lazaretti-Castro, J. G. H. Vieira,
and I. P. Heilberg, “Response to an oral calcium load in
nephrolithiasispatientswithﬂuctuatingparathyroidhormone
and ionized calcium levels,” Brazilian Journal of Medical and
Biological Research, vol. 37, no. 9, pp. 1379–1388, 2004.
[14] N. Cusano, P. Wang, S. Cremers et al., “Asymptomatic nor-
mocalcemic primary hyperparathyroidism: characterization
of a new phenotype of normocalcemic primary hyperparathy-
roidism,” Journal of Bone and Mineral Research, vol. 26,
supplement 1, abstract 290, 2011.